Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia

Risk factors for infections with extended- spectrum beta-lactamase-producing Escherichia coli in a county of Southern Sweden

(2013) Johan Tham et al.   Infection and Drug Resistance

Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study

(2012) Galo Peralta et al.   BMC INFECTIOUS DISEASES

Fourteen years in resistance

(2012) David M. Livermore   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis

(2012) Wouter C. Rottier et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Identifying Patients Harboring Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae on Hospital Admission: Derivation and Validation of a Scoring System

(2011) Mario Tumbarello et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase–producing Escherichia coli or Klebsiella pneumoniae

(2011) Nan-Yao Lee et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: Incidence, risk factors and its impact on outcome

(2011) Prashant Nasa et al.   European Journal of Internal Medicine

Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa

(2011) Souha S. Kanj et al.   MAYO CLINIC PROCEEDINGS

Foreign Travel Is a Major Risk Factor for Colonization with Escherichia coli Producing CTX-M-Type Extended-Spectrum  -Lactamases: a Prospective Study with Swedish Volunteers

(2010) T. Tangden et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis

(2010) M. Paul et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

National Multicenter Study of Predictors and Outcomes of Bacteremia upon Hospital Admission Caused by Enterobacteriaceae Producing Extended-Spectrum  -Lactamases

(2010) D. Marchaim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis

(2010) S. T. Micek et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Influence of Empiric Therapy with a  -Lactam Alone or Combined with an Aminoglycoside on Prognosis of Bacteremia Due to Gram-Negative Microorganisms

(2010) J. A. Martinez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Costs of Bloodstream Infections Caused by Escherichia coli and Influence of Extended-Spectrum- -Lactamase Production and Inadequate Initial Antibiotic Therapy

(2010) M. Tumbarello et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals

(2010) J. Rodríguez-Baño et al.   CLINICAL MICROBIOLOGY AND INFECTION

Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins

(2010) M. E. A. de Kraker et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes

(2010) C. Gudiol et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Risk Factors and Prognosis of Nosocomial Bloodstream Infections Caused by Extended-Spectrum- -Lactamase-Producing Escherichia coli

(2010) J. Rodriguez-Bano et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Clinical Implications, Risk Factors and Mortality Following Community-onset Bacteremia Caused by Extended-spectrum β-lactamase (ESBL) and non-ESBL Producing Escherichia coli

(2010) Chia-Jung Hsieh et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

A Multinational Survey of Risk Factors for Infection with Extended‐Spectrum β‐Lactamase–Producing Enterobacteriaceae in Nonhospitalized Patients

(2009) Ronen Ben‐Ami et al.   CLINICAL INFECTIOUS DISEASES

Community‐Onset Bacteremia Due to Extended‐Spectrum β‐Lactamase–ProducingEscherichia coli:Risk Factors and Prognosis

(2009) Jesús Rodríguez‐Baño et al.   CLINICAL INFECTIOUS DISEASES

The changing epidemiology of resistance

(2009) P. M. Hawkey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Bloodstream Infections Caused by Extended-Spectrum- -Lactamase- Producing Escherichia coli: Risk Factors for Inadequate Initial Antimicrobial Therapy

(2008) M. Tumbarello et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Gram-negative bacteraemia in non-ICU patients: factors associated with inadequate antibiotic therapy and impact on outcomes

(2008) J. Marschall et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern

(2008) Johann DD Pitout et al.   LANCET INFECTIOUS DISEASES